In addition, somatic mutations (mainly BRCA2 and ATM genes) have been described in 19% of patients with localized PC and 23% of mCRPC, so these findings should not be strictly considered critical for AS exclusion [15,97,98]. The gene discussed is BRCA2; the disease is pachyonychia congenita.